Fuad El-Hibri Wire » Fuad Elhibri

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

admin — Thu, 07 Jul 2011 14:28:52 +0000

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23^rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax^(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.

“Emergent is pleased with this development as it continues to grow its presence in the Pacific Rim,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “With HSA approval of BioThrax, we look forward to initiating discussions with the government of Singapore, as well as other allied governments that recognize HSA registered products such as Brunei, to help protect their constituents against the threat of anthrax as a biological weapon.”

HSA is the statutory board of the Singapore Ministry of Health that administers the country’s regulatory framework for pharmaceuticals, complementary medicines, medical devices and other health products. Its vision is to be the leading innovative authority that protects and advances national health and safety in Singapore.

About Emergent BioSolutions Inc.

Emergent BioSolutions, led by Chairman and CEO Fuad El-Hibri protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at http://www.emergentbiosolutions.com.

About BioThrax

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 42 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts. Since 1998, over 10 million doses have been administered to more than 2.5 million military personnel. For full prescribing information, please visit http://www.biothrax.com/prescribinginformation_biothrax_us.pdf.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2011, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax^(R) procurement; our ability to obtain new BioThrax^(R) sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax^(R); our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance of our products; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions...
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS)...

Related posts brought to you by Yet Another Related Posts Plugin.

Fuad El-Hibri’s Linkedin Profile

admin — Tue, 18 Aug 2009 12:10:52 +0000

Fuad El-Hibri

Chairman and Chief Executive Officer at Emergent BioSolutions Inc.

Greater Seattle Area

Fuad El-Hibri is currently Chairman and Chief Executive Officer at Emergent BioSolutions Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares

admin — Fri, 14 Aug 2009 10:29:38 +0000

CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.

EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.

Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript

admin — Fri, 14 Aug 2009 10:00:15 +0000

Emergent BioSolutions Inc., (EBS)

Q2 2009 Earnings Call

August 6, 2009 5:00 pm ET

Executives

Robert G. Burrows – Vice President, Investor Relations

Fuad El-Hibri – Chairman of the Board, Chief Executive Officer

R. Don Elsey – Chief Financial Officer

Daniel J. Abdun-Nabi – President, Chief Operating Officer

W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer

Analysts

Eric Schmidt – Cowen & Company

David Moskowitz – Caris & Company

Mona Ashiya – J.P. Morgan

Sean Long – Kennedy Capital Management

Presentation

Operator

Welcome to the Emergent BioSolutions Incorporated second quarter 2009 financial results conference call. (Operator Instructions) I would now like to turn the call over to Mr. Robert Burrows.

Robert Burrows

Good afternoon ladies and gentlemen. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss Emergent BioSolutions financial results for the second quarter and first six months of 2009. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions.

Joining me on the call this afternoon will be Fuad El-Hibri, Chairman and Chief Executive Officer, and Don Elsey, Chief Financial Officer. Additional members of our senior management team will be present on the call for purposes of the Q&A session.

Before we begin, however, I am compelled to remind everyone that during the all management may make projections and other forward-looking statements regarding future events and the company’s prospects or future performance. These forward-looking statements reflect Emergent’s current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions Reports Financial Results for Full Year 2010 2010 revenues of $286.2 million 2010 net income of...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012 ROCKVILLE, Md.–(BUSINESS WIRE)–Jan. 30, 2012– Emergent BioSolutions Inc. (NYSE: EBS)...

Related posts brought to you by Yet Another Related Posts Plugin.

Fuad El-Hibri Ernst & Young Entrepreneur of the Year

admin — Mon, 22 Jun 2009 01:36:02 +0000

Emergent BioSolutions chairman and CEO, Mr. Fuad El-Hibri, named Ernst & Young Entrepreneur of the Year 2009 award finalist in greater Washington. Emergent BioSolutions chairman Fuad El-Hibri:

Mr. Fuad El-Hibri named Ernst & Young Entrepreneur of the Year 2009 award finalist in greater Washington

ROCKVILLE, Md. – (BUSINESS WIRE) – Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year Awards Program

Ernst & Young’s Entrepreneur of the Year Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Comment on this story, by email comment@newsblaze.com

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.

Ernst & Young’s Entrepreneur of the Year Fuad El-Hibri

admin — Mon, 22 Jun 2009 01:32:17 +0000

chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year^® 2009 Award in the Greater Washington region. Yahoo! Finance and Mr. Fuad El-Hibri:

Emergent BioSolutions Inc. (NYSE:EBS – News) announced today that its. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year^® Awards Program

Ernst & Young’s Entrepreneur of the Year^® Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year^® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.

Board expands with Election of Fuad El-Hibri

admin — Mon, 22 Jun 2009 01:16:06 +0000

NHM Chairman Louis Sullivan, MD, has announced the election of biotechnology executive Fuad El-Hibri, physician and public health expert Margaret A. Hamburg, MD, and technology entrepreneur James M. Philips to the NHM Board of Trustees for three-year terms of service. Fuad El-Hibri on National Health Museum, WASHINGTON— September 3, 2007.

Fuad
El-Hibri

Margaret Hamburg

James
Philips

“As we continue working toward our goal of an institution that will serve as a global information platform, we celebrate the election of three new board members who have each made key contributions to the creation of a healthier and safer world,” said Sullivan.

“Through his leadership in the field of biotechnology, Fuad El-Hibri is helping develop strategies to address serious threats to global health security. Throughout a distinguished career in public service, Peggy Hamburg has focused her considerable intellect and medical training on similar concerns as well as a range of other pressing health policy issues. And from his position at the vanguard of the information technology revolution, Jim Phillips has helped successfully launch companies and institutions that are improving our ability to connect, communicate and heal.

“We are proud to have earned the active interest and support of Fuad, Peggy and Jim and look forward to drawing extensively upon their experience and expertise as our efforts to develop NHM proceed,” said Sullivan.

Fuad El-Hibri, CEO and Chairman, Emergent Biosolutions

Fuad El-Hibri leads Emergent Biosolutions, a Maryland-based biotechnology company focused on the development, manufacture and commercialization of immunobiotics. The company operates in two business segments: biodefense and commercial. In its biodefense business, Emergent develops and commercializes immunobiotics for use against biological agents that are potential weapons of bioterrorism. In its commercial business, the company develops immunobiotics for use against infectious diseases with significant unmet or underserved medical needs.

El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from 1998 until 2004, when BioPort became a subsidiary of Emergent. He also served as chairman of Digicel Holdings, Ltd., a privately held cellular telecommunications firm, from August 2000 to October 2006. Since 1990, he has also served as chairman of East West Resources Corporation, a venture capital and financial consulting firm.

He is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation which has contributed to a variety of international development projects, including a children’s orphanage in Lebanon. He holds a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.

Margaret A. Hamburg, MD, Senior Scientist, Global Health and Security Initiative, NTI

One of the youngest people ever elected to the Institute of Medicine of the National Academy of Sciences, Dr. Margaret “Peggy” Hamburg is a highly regarded expert in community health and bio-defense, including preparedness for nuclear, biological, and chemical threats. She currently serves as Senior Scientist for the Global Health and Security Initiative of the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons. A graduate of Radcliffe College, she earned her M.D. from Harvard Medical School, and completed her training at the New York Hospital/Cornell University Medical Center.

From 1997 to 2001, Hamburg held the position of Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services (HHS), serving as principal policy advisor to Secretary of Health and Human Services Donna Shalala. From 1991 to 1997, she served as New York City Health Commissioner, a position in which she designed and implemented an internationally recognized tuberculosis control program that produced dramatic declines in tuberculosis cases, and created the first public health bio-terrorism preparedness program in the nation. Between 1986 and 1990, she held a variety of positions within HHS, including Special Assistant to the Director, Office of Disease Prevention and Health Promotion; and Special Assistant to the Director, and later Assistant Director, of the National Institute of Allergy & Infectious Diseases at the National Institutes of Health.

A member of the Harvard College Board of Overseers and the Boards of Trustees of Rockefeller University and the Rockefeller Foundation, Hamburg is also a distinguished senior fellow with the Center for Strategic and International Studies, and a fellow of the American Association of the Advancement of Science. She holds membership in the New York Academy of Medicine, and the Council on Foreign Relations and serves on the board of Henry Schein Company. She has served on the boards of other organizations, including the New York City Health and Hospitals Corporation, the Nathan Cummings Foundation, the Primary Care Development Corporation, and the Board of Scientific Counselors for the National Center for Infectious Diseases of the Centers for Disease Control and Prevention.

James M. Phillips, Vice Chairman, Luminetx

James “Jim” Phillips’s career has been marked by success at starting and guiding companies through successful initial public offerings and pioneering new technologies into major industry-leading positions – including the PDA, digital cell phone, fixed cellular and internet multimedia. A classic entrepreneur, Phillips’ began his career with Telecommunications System of America, which was sold to Northern Telecom (Nortel), where Phillips eventually became vice president. He held subsequent executive positions at SkyTel, which became the nation’s largest messaging company; Telular Corporation, the world’s largest fixed wireless cellular company; and Motorola, where he participated in launching digital cellular and multimedia, bringing cable modem to the market.

Phillips then became Chairman and CEO of IPIX, which produced digital photographs with 360° navigable images that are today widely used on major Web sites. After taking the company public, he was asked to become involved with the effort to build the FedEx Institute of Technology (FIT), a partnership between Federal Express Corp. and The University of Memphis. Phillips resigned from IPIX, moved to Memphis and raised $100 million to make FIT a reality. Information Week has called FIT the technology industry’s “newest center for innovation” and WIRED has compared it to the famous Media Lab at MIT.

After successfully launching FIT, Phillips served as CEO in residence at Morgan Keegan, a Memphis-based investment firm, before raising the capital to launch Luminetx Corporation. Luminetx produces the VeinViewer, which was named in 2004 by Time as “one of the coolest medical inventions of the year.” Phillips is Vice Chairman of Luminetx, having previously served as the company’s CEO, president and chairman. A holder of patents in cell phone, PDA and data modem design, he also serves on a number of boards including the American Museum of Science and Energy, Visio Technologies Corporation, EmergeMemphis, Memphis Biotech Foundation, University of Memphis Fogelman School of Business and Economics, and the Memphis Area Chamber of Commerce.

Posted in American University, El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: United States, National Institutes of Health, United States Department of Health and Human Services, Centers for Disease Control and Prevention, Rockefeller Foundation, Harvard Medical School, Hamburg, United States Secretary of Health and Human Services

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.

Emergent Biosolutions El-Hibri

admin — Mon, 22 Jun 2009 00:54:13 +0000

Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock:

On January 20, 2009, Emergent Biosolutions announces that Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock: 13.5 million shares had been issued to date with 47% controlled by Fuad El-Hibri. It also announced Stage II testing of vaccines for Typhoid, Hepatitis B, and Tuberculosis.

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June...
Emergent BioSolutions Reports Financial Results for Full Year 2010 2010 revenues of $286.2 million 2010 net income of...

Related posts brought to you by Yet Another Related Posts Plugin.

Fuad El-Hibri El-Hibri Peace Education Prize

admin — Mon, 22 Jun 2009 00:44:16 +0000

At a glittering event at the El-Hibri Charitable Foundation on October 4th, a few blocks north of the White House, the Honorable R. Scott Kennedy received the 2008 El-Hibri Peace Education Prize. This prize, a joint effort between Nonviolence International, American University, and the El-Hibri family, was held in front of a large crowd in the renovated historic mansion that now serves as the headquarters of the Fuad El-Hibri and family’s El-Hibri Charitable Foundation.

Fuad El-Hibri and the 2008 El-Hibri Peace Education Prize

R. Scott Kennedy Awarded the 2008 El-Hibri Peace Education Prize

Ms. Nancy El-Hibri, co-creator of the Prize, presented Mr. Kennedy a check for $10,000 which honored his service as a “peace educator and activist of extraordinary impact.” The award presentation ceremony highlighted his central role in “helping establish and promote the now widespread practice of educational delegations for peace particularly to Central America and the Middle East.”

The Honorable Sam Farr of California entered a congratulatory statement in the Congressional Record which paid tribute to Mr. Kennedy and compared his work to that of Mohandas Gandhi, Martin Luther King, Jr. and Nelson Mandela as a “…true man of peace…”

“His devotion to adult education has changed the lives of thousands of Americans,” said Dr. Mubarak Awad, Chairperson of the Prize Organizing Committee.

The first recipient of the prize in 2007, Professor Abdul Aziz Said of American University, shared his appreciation for peace educators who are doing so much to, “expand the moral imagination of our society.”

“Peace education in the classroom is valuable, yet needs to be complemented with pragmatic hands-on efforts in our communities to make peace and justice a living reality,” said Kennedy at the award ceremony. He expressed deep appreciation for the many colleagues at the Resource Center for Nonviolence as well as the citizens of Santa Cruz for their tremendous support and inspiration over 30 years.

Mr. Fuad El-Hibri, who established the El-Hibri Peace Education Prize, noted that he and the El-Hibri Charitable Foundation will continue to support the prize and its growth each year in an effort to highlight the importance of peace education and to support people who are working for a just, peaceful and healthy planet.

Mr. R. Scott Kennedy is a co-founder of Witness for Peace, the Resource Center for Nonviolence and Interfaith Peacebuilders, which have sent educational delegations to countries around the world to those countries whose people suffer from conflict, lack of educational opportunities, and social injustice.

It sure is wonderful when adult peace education is so strongly honored, and that peace educators have incorporated nonviolent action as a central theme in their work.

Posted in El-Hibri Foundation, El-Hibri Fuad, El-Hibri Peace Education Prize, Fuad El-Hibri
Tags: American University, Martin Luther King, Nelson Mandela, Nonviolence, Mohandas Karamchand Gandhi, Mubarak Awad, Nonviolence International, White House

FUAD EL-HIBRI TO AWARD 2011 EL-HIBRI PEACE EDUCATION PRIZE TO GENE SHARP The El-Hibri Charitable Foundation has announced that internationally acclaimed author...

Related posts brought to you by Yet Another Related Posts Plugin.

Fuad El-Hibri Earnings Call

admin — Mon, 22 Jun 2009 00:14:47 +0000

Good afternoon everyone. As Fuad mentioned following the close of … timing and the potential opportunity? Fuad El-Hibri Indeed, AIG remains a … or another contract for BioThrax. Fuad El-Hibri Fuad El-Hibri and Emergent BioSolutions Inc. Earnings Call Transcript

… in continued profitability. Finally, as Fuad mentioned, we continue to pursue … upfront versus development versus procurement? Fuad El-Hibri Well, let me first … Have you gone to that? Fuad El-Hibri For competitive reasons, I …

Emergent BioSolutions Inc. Q3 2008 Earnings Call Transcript 21 Nov, 2008

… , and our recombinant trivalent botulinum vaccine. As Fuad mentioned these development contract revenues carry with … a protest. Cory Kasimov – JPMorgan Right. Okay. Fuad El-Hibri (inaudible). Cory Kasimov – JPMorgan …

Emergent BioSolutions Inc. Q2 2008 Earnings Call Transcript 07 Aug, 2008

… Robert Burrows – VP, Corporate Communications Fuad El-Hibri – Chairman and CEO Don … follows Following my brief introduction, Fuad will provide comments on corporate … Company And I take from Fuad’s comments that you’re …

Emergent BioSolutions Inc. Q1 2008 Earnings Call Transcript 07 May, 2008

… Robert Burrows – VP, Corporate Communications Fuad El-Hibri – Chairman and CEO Don … the call this morning is Fuad El-Hibri, our Chairman and Chief … sales, not in the quarter-over-quarter. Fuad El-Hibri Yes, that’s absolutely …

Emergent Biosolutions Inc. Q4 2007 Earnings Call Transcript 07 Mar, 2008

… third generation anthrax vaccine, please. Fuad El-Hibri Thank you Richard, I … military for [executive] immunization program. Fuad El-Hibri I guess the best … monopolizing on the time here. Fuad El-Hibri You’re asking some …

Emergent Biosolutions Q3 2007 Earnings Call Transcript 02 Nov, 2007

… straightforward. Following my brief introduction, Fuad will briefly discuss third quarter … to the discounted price that Fuad indicated earlier. This discounted price … is this a new customer? Fuad El-Hibri What I can disclose …

Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012 ROCKVILLE, Md.–(BUSINESS WIRE)–Jan. 30, 2012– Emergent BioSolutions Inc. (NYSE: EBS)...
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions...

Related posts brought to you by Yet Another Related Posts Plugin.